Fig. 6.

Class II HDAC inhibitors reverse chemotherapy promoted CSL traits in ER+ and TNBC cells. Time-course curves of relative fold changes for FACS mean values of ALDH and CD44, and CSL/Live were shown for chemotherapy plus LMK235 and CAY10693 treatments in CAMA-1 (A, B) and MDA-MB-231 (C, D). Both cell lines were cultured in medium (3D) and treated for 72 h with doxorubicin (0.1 µM for CAMA-1, 0.5 µM for MDA-MB-231), carboplatin (50 µM), and paclitaxel (1 µM), and then replaced with medium containing LMK-235 (5 µM) or CAY10603 (5 µM) for 72 h incubation. Samples were collected every day from Day 1 to Day 6, and followed by ALDEFLUOR/CD44/DAPI staining and FACS analysis. DMSO treatment only in each day served as control and was set as fold one. All the other treatments were expressed as the fold values relative to the controls. Each spot represents the mean values of triplicate tests. The differences between chemo plus DMSO (9 replicates from three chemo plus DSMO) and chemo plus belinostat (9 replicates from three chemo plus belinostat) at Day 6 were evaluated by student's T tests. Significance is marked with * for P<0.05, ** for P<0.01, *** for P<0.001, **** for P<0.0001. .